Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …

The human immunodeficiency virus (HIV) is responsible for acquired immune deficiency
syndrome (AIDS), one of the major pandemic diseases. Highly active antiretroviral therapy …

HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …

HIV reverse transcriptase (RT) is an enzyme that plays a major role in the replication cycle of
HIV and has been a key target of anti-HIV drug development efforts. Because of the high …

Currently, HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a major
component of the highly active anti-retroviral therapy (HAART) regimen. However, the …

Integrase strand transfer inhibitors (INSTIs) are currently recommended for the first line
treatment of human immunodeficiency virus type one (HIV-1) infection. The first-generation …

The human immunodeficiency virus (HIV) persists in latently infected CD4+ T cells and
integrates with the host genome until cell death. Acquired immunodeficiency syndrome …

The development of efficacious NNRTIs for AIDS therapy commonly encountered the rapid
generation of drug-resistant mutations, which becomes a major impediment to effective anti …

During HIV-1 genome replication, the viral reverse transcriptase-associated ribonuclease H
(RT-associated RNase H) activity hydrolyzes the RNA strand of RNA/DNA heteroduplex …

Nucleoside and nucleotide analogues are essential antivirals in the treatment of infectious
diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C …